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THE DEVELOPMENT OF A NOVEL THERAPEUTIC FOR THE 
TREATMENT OF SICKLE CELL DISEASE 
Steven Sturlis and Brian Brennan* 
Chemistry Department, Illinois Wesleyan University 
Sickle Cell Disease is ' a genetic disorder caused by a single point mutation that affects the 
hemoglobin of red blood cells. This mutation allows the protein to interact with other molecules 
of hemoglobin, forming aggregates that take on a gel like consistency within the cells. The 
protein aggregation deforms the cell, changing it from a normal biconcave disc form to a 
' sickled' shape, leading to improper flow through capillaries. Despite the fact that the molecular 
mechanism for the illness has been known in detail since 1957, no truly effective treatment has 
yet been discovered. As a novel approach for the treatment of this ailment, we have taken 
advantage of a peptide screen in order to discover ligands that can bind to the protein surface and 
disrupt the protein�protein interactions responsible for aggregation. Our initial library is based 
on the natural peptide sequence of the mutation binding site. 
